THIS MONTH’S ISSUE

Read, save, and print articles from the current issue

ARTICLES

Chronological index
2013–2018

PRODUCT GUIDES

Compare all instruments
and software systems

DEPARTMENTS

Chronological index
2013–2018

WEBINARS

Register Now and
On Demand

Home » MARKETPLACE, Marketplace Archives

ArcherDx, Ambry Genetics partnership, 5/18

 

May 2018—ArcherDx and Ambry Genetics announced a partnership in which Ambry will provide biopharma sequencing services using ArcherDx’s next-generation sequencing assays. Ambry Genetics will utilize Archer Immunoverse and VariantPlex NGS assays to provide large-scale immune repertoire analysis and chimeric antigen receptor T-cell manufacturing characterization and pharmacodynamics to biopharma customers.

The assays are based on ArcherDx’s Anchored Multiplex PCR technology and will target B- and T-cell receptor complementarity-determining regions to assess quantitative changes in the immune repertoire. The technology will also target CAR-T vectors to investigate the engineered T-cell repertoire over the course of autologous CAR-T cell manufacturing and treatment. Archer assays will also map the diversity of CAR-T integration sites and estimate the transduction efficiency and copy number of integration events.

ArcherDx, 303-357-9001

Ambry Genetics, 949-900-5500

Print Friendly, PDF & Email
Tags: ,

X